Form 4: ZyVersa Therapeutics CFO Peter Wolfe Granted 60,100 Stock Options

Peter Wolfe, Chief Financial Officer of ZyVersa Therapeutics, Inc., was granted 60,100 stock options with an exercise price of $0.59 per share, vesting over three years.

Summary

• Peter Wolfe, the Chief Financial Officer of ZyVersa Therapeutics, Inc. (ZVSA), was the reporting person for this transaction.
• On July 11, 2025, Mr. Wolfe acquired 60,100 stock options.
• The exercise price for these stock options is $0.59 per share.
• The options vest in equal annual installments on the first three anniversaries of the grant date, subject to Mr. Wolfe's continued service.
• The expiration date for these stock options is July 11, 2035.
• Following this transaction, Mr. Wolfe beneficially owns 60,100 derivative securities (stock options) and 60,100 underlying shares of common stock.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is a standard and generally positive practice for aligning management interests with shareholder value. It signals executive retention and commitment, though it does not directly reflect financial performance.

Positives

• The grant of stock options to the Chief Financial Officer aligns management's long-term interests with those of shareholders.
• The 10-year expiration period for the options provides a significant long-term incentive for the executive.

Risks

• The vesting of the stock options is contingent upon the Chief Financial Officer's continued service with the company, meaning unvested options could be forfeited if employment ceases.
• The value of the stock options is dependent on the future market price of ZyVersa Therapeutics' common stock exceeding the $0.59 exercise price.

Future Outlook

The vesting schedule of the stock options over three years indicates a commitment to the Chief Financial Officer's continued service and incentivizes long-term performance and retention. The options themselves provide a long-term incentive for the executive to contribute to the company's growth.

Industry Context

Granting stock options to key executives is a common practice across industries, particularly in biotechnology and pharmaceutical sectors, to attract, retain, and incentivize talent. This aligns executive compensation with shareholder value creation over the long term, which is crucial for companies with extended development cycles.

Related Party Transactions

• The grant of 60,100 stock options to Peter Wolfe, the Chief Financial Officer, constitutes a transaction with a related party as part of his compensation.

Stakeholder Impact

• Shareholders: The stock option grant aims to align the Chief Financial Officer's financial incentives with the long-term performance and value creation for shareholders.
• Employees: This transaction is specific to executive compensation and does not directly impact other employees, though it reflects standard executive incentive practices.

Next Steps

• Peter Wolfe's continued service with ZyVersa Therapeutics for the stock options to vest according to the schedule.
• Future disclosures of any changes in Peter Wolfe's beneficial ownership of ZyVersa Therapeutics securities.

Key Dates

Keywords

ZyVersa Therapeutics, ZVSA, Peter Wolfe, Stock Options, SEC Form 4, Insider Transaction, Executive Compensation, Chief Financial Officer, Equity Grant